drugset
drugset / Trial / NCT03224793

Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.

NCT03224793 ↗

Phase 1 Completed 32 enrolled Biogen
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the safety and tolerability of single, subcutaneous (SC) doses of BIIB059 in healthy Japanese subjects.

Timeline

Start
2017-10-04
Primary completion
2018-06-12
Completion
2018-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Litifilimab Monoclonal antibody 20 mg Subcutaneous
Subject Litifilimab Monoclonal antibody 50 mg Subcutaneous
Subject Litifilimab Monoclonal antibody 150 mg Subcutaneous
Subject Litifilimab Monoclonal antibody 450 mg Subcutaneous

Indications

No indication recorded.